A Phase 2a, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06687234 As Add-on Therapy To Infliximab In Active Ulcerative Colitis Subjects Who Are Not In Remission (BUILD UC)
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs F8 IL10 (Primary) ; F8 IL10 (Primary) ; Infliximab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms BUILD UC
- Sponsors Pfizer
- 03 Jan 2019 Planned number of patients changed from 76 to 68.
- 02 Oct 2018 Planned number of patients changed from 98 to 76.
- 12 Jan 2018 Planned number of patients changed from 68 to 98.